These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9093099)

  • 1. Hypoglycaemia associated with formestane treatment.
    Brankin E; Gallagher A; Soukop M
    BMJ; 1997 Mar; 314(7084):869. PubMed ID: 9093099
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe immune thrombocytopenia during formestane treatment.
    Español I; Muñíz-Díaz E; Alonso MC; Pujol-Moix N
    Haematologica; 1998 Oct; 83(10):953-4. PubMed ID: 9830809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced breast cancer with formestane.
    Murray R; Pitt P
    Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formestane for advanced breast cancer in postmenopausal women.
    Drug Ther Bull; 1993 Oct; 31(22):85-7. PubMed ID: 8269826
    [No Abstract]   [Full Text] [Related]  

  • 5. Pilot study of formestane in postmenopausal women with breast cancer.
    Joseph JK; Lim AK
    Med J Malaysia; 1998 Mar; 53(1):37-41. PubMed ID: 10968135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
    Wiseman LR; Goa KL
    Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
    Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
    Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
    Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
    Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formestane in the treatment of advanced postmenopausal breast cancer.
    Possinger K; Jonat W; Höffken K
    Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
    Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
    Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
    Wiseman LR; McTavish D
    Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of novel 4-amino-4,6-androstadiene-3,17-dione: an analog of formestane.
    Sharma SK; Zheng W; Joshua AV; Abrams DN; McEwan AJ
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5563-6. PubMed ID: 18815032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
    Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
    Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane.
    Dowsett M
    Ann Oncol; 1994; 5 Suppl 7():S3-5. PubMed ID: 7873460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
    Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
    Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical trial of lentaron for postmenopausal patients with advanced breast cancer].
    Liu X; Song S; Jiang Z; Wu S; Yu J; Wang T
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):511-3. PubMed ID: 12485513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
    Bernhard J; Thürlimann B; Schmitz SF; Castiglione-Gertsch M; Cavalli F; Morant R; Fey MF; Bonnefoi H; Goldhirsch A; Hürny C
    J Clin Oncol; 1999 Jun; 17(6):1672-9. PubMed ID: 10561203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
    Höffken K; Jonat W; Possinger K; Kölbel M; Kunz T; Wagner H; Becher R; Callies R; Friederich P; Willmanns W
    J Clin Oncol; 1990 May; 8(5):875-80. PubMed ID: 2185341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma.
    Nisslein T; Freudenstein J
    Planta Med; 2007 Apr; 73(4):318-22. PubMed ID: 17354167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the treatment and palliation of advanced breast cancer. Symposium proceedings. Jerusalem, 1993.
    Ann Oncol; 1994; 5 Suppl 7():S1-55. PubMed ID: 7532990
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.